Accumulating evidence in animal models and human asthma support a central role for IL-13 signaling in disease pathogenesis. In order to identify asthma and therapy associated genes, global transcriptional changes were monitored in mouse lung following antigen challenge (ovalbumin (OVA)), either alone or in the presence of a soluble IL-13 antagonist. Changes in whole lung gene expression after instillation of mIL-13 were also measured both in wild type and STAT6 deficient mice. A striking overlap in the gene expression profiles induced by either OVA challenge or mIL-13 was observed, further strengthening the relationship of IL-13 signaling to asthma. Consistent with results from functional studies, a subset of the OVA-induced gene expression was significantly inhibited by a soluble IL-13 antagonist while IL-13-modulated gene expression was completely attenuated in the absence of STAT6-mediated signaling. Results from these experiments greatly expand our understanding of asthma and provide novel molecular targets for therapy and potential biomarkers of IL-13 antagonism.
Introduction
Asthma is a chronic inflammatory disease of the lung characterized by recurrent episodes of reversible airway obstruction and airway hyper-responsiveness (AHR). Typical clinical manifestations include shortness of breath, wheezing, coughing and chest tightness that can become life threatening or fatal. [1] [2] [3] Despite major advances in therapy and considerable progress in understanding the role of genetics and the environment in evoking asthma, the prevalence, morbidity and mortality of the disease continue to increase. Thus, a clear need exists for better understanding of asthma pathogenesis and identification of new approaches to its therapeutic management. 4, 5 The mechanisms of allergic asthma have been studied in the murine model, where animals are sensitized by intraperitoneal (i.p.) injection of ovalbumin (OVA) in the presence of adjuvant, subsequently challenged by intratracheal administration of OVA and responses monitored. This procedure generates a CD4 þ T-cell mediated T H 2 immune reaction in the lung with increased serum IgE, eosinophilia, excessive mucus secretion, and AHR similar to human asthma. We have demonstrated the inability of intratracheal OVA-challenge to elicit eosinophil infiltration, mucus hypersecretion and airway hyper-reactivity in mice deficient in either CD4 þ T-cells, IL-4 receptor or STAT6. [4] [5] [6] [7] The T H 2 cytokine IL-13 plays a central role in this model as administration of a soluble IL-13 antagonist (sIL-13Ra2-Fc) completely blocked OVAchallenge induced goblet cell mucus metaplasia and AHR, while intratracheal instillation of mIL-13 fully replicated asthma-related pathologies. 8, 9 These results are consistent with the fact that STAT6 activation is downstream of IL-4Ra-mediated signaling and that IL-13 is required for OVA induced AHR and mucus production. 5, 10 Recent genetic studies in man have demonstrated an association between specific alleles of IL-13 and its signaling components with asthma and atopy, suggesting an important role for this pathway in the human disease. 11 Global transcriptional profiling using oligonucleotide microarrays 12 provides a powerful tool to elucidate novel disease-related genes and pathways within complex tissues. 13 Because instillation of IL-13 to the lung recapitulates the asthma phenotype and administration of an IL-13 antagonist blocks OVA-challenge induced lung pathology, we investigated the expression profiles associated with disease induction and therapeutic intervention. The majority of pulmonary gene expression changes associated with the OVA-mediated response, with the exception of immunoglobulins, were also induced by IL-13 instillation. However, only a subset of disease-related genes was identified whose expression was altered by blockade of IL-13 signal transduction.
Results
Identification of asthma and therapy-associated gene expression Expression profiles were determined from lung tissue 3 days after mice were challenged with either PBS (buffer control) or OVA and treated with either the IL-13 antagonist (sIL13Ra2-Fc) or human IgG. To identify asthma-associated transcripts, the average lung mRNA frequencies from PBSchallenged mice (control) were compared with OVA-challenged mice (OVA). Following OVA-challenge, 113 probe sets exhibited an average fold change (AFC) of two-fold or greater and Students t-test Po0.05. False discovery rate (FDR) was calculated by random permutation of input data (10 000 randomly reassigned groups) and determining median number of genes jointly meeting t test and foldchange criteria.
14 The OVA modulated gene set was further filtered to remove genes with an FDR of greater than 5% resulting in an OVA-challenged set with 88 probe sets. Following sequence annotation, genes identified multiple times were removed and the unique set of significant changes in lung gene expression following OVA challenge is reported in Table 1 . In total, 40 distinct probe sets identified immunoglobulin mRNA increases. Only the top five Ig sequences as defined by fold-change are reported in Table 1 . As observed at the transcriptional level, the pulmonary allergic response upregulates a diverse set of genes with only three transcripts statistically significantly decreased (Table 1) . Annotation of the allergic gene set reveals multiple members of functionally related families including immunoglobulins, Fc receptors, proteases, protease inhibitors, complement, chitinase-related proteins, and several secreted signaling proteins including chemokines and trefoil factors. The biological relevance of this transcriptional profile is supported by the observation that many of the genes and nearly all of the functional categories identified in this study have been shown to be associated with asthma, epithelial cell metaplasia, eosinophilia or airway hyperreactivity (AHR). This analysis also identified additional genes not previously associated with the allergic response.
To determine changes in gene expression associated with resolution of AHR and mucus metaplasia in murine asthma, we compared pulmonary gene expression in OVA-challenged mice in the presence or absence of sIL-13Ra2-Fc treatment ( Table 1) . Administration of sIL-13Ra2-Fc completely inhibited only a subset of the OVA-induced genes. Of 32 transcripts induced following OVA challenge, 17 were reduced greater than 40% by sIL-13Ra2-Fc treatment. Many of the genes modulated by anti-IL-13 therapy have been associated with epithelial mucus production (AGR/Gob-4, CLCA3/Gob-5, trefoil factors 1 and 2 and Reg III gamma) and an immunoglobulin response. OVA-induced genes associated with the immune response, including chemokines, proteases, protease inhibitors and complement C1q, showed little or no response to blockade of IL-13 signaling. The inhibition of OVA-induced gene expression was specific to treatment with the IL-13 antagonist and not affected by the Fc-fusion moiety. To illustrate this point, gene frequency measurements for each of the experimental subgroups for 20 genes showing the highest fold-change following intratracheal OVA-challenge are shown in Figure 1 .
Gene expression changes in mouse lung induced by mIL-13 instillation Intratracheal administration of IL-13 recapitulates the asthma phenotype induced by allergen challenge. To identify transcriptional changes associated with the pulmonary response to IL-13 and to determine the role of STAT6 signaling on this transcriptional response, mice were treated at 0, 24 and 48 h with 5 mg of recombinant mIL-13 or PBS prior to harvesting of lungs at 72 h. Comparison of gene expression profiles from wild-type mice treated by intratracheal instillation of mIL-13 or buffer-alone identified 145 transcripts with AFC greater than two-fold (Po0.05). Selection for FDR o5% reduced the IL-13 modulated probe sets to 116 sequences. The nonredundant gene set modulated by intratracheal IL-13 instillation is reported in Table 2 sorted generally by functional annotation. All of the statistically significant changes in gene expression represent increases in transcript levels mediated by mIL-13 instillation except for a decrease in NAD þ -dependent hydroxyprostaglandin dehydrogenase (HPGD) expression.
Many of the genes in the IL-13 induced gene set fall within and expand the same functional categories identified by the OVA-challenge allergic reaction. Additional Tables 1 and 2 reveals a large degree of overlap in gene expression induced by allergen (OVA) challenge and IL-13 instillation consistent with the finding that OVA challenge and IL-13 induce similar asthma phenotypes. Of the 27 nonimmunoglobulin genes induced following OVA-challenge, 20 demonstrated statistically significant two-fold or greater induction following IL-13 instillation. Table 3 identifies the genes responsive to both OVA-challenge and IL-13 instillation with fold-changes measured for the common allergen/IL-13 induced pulmonary transcriptome depicted in Figure 2 . Examining the pattern of inhibition of OVA-induction in these genes by the IL-13 antagonist (sIL-13Ra2) defines classes of transcriptional response (Table 3) . For genes such as CLCA3, AGR2, PIGR and trefoil factors, IL-13 is both sufficient and required Table 1 . Gene expression in murine asthma models for transcriptional induction. For other genes commonly modulated, however, including the chemokines (SCYA6, SCYA9) and protease inhibitors, IL-13 is sufficient for induction but not required in the context of allergenchallenge. STAT-6 dependent IL-13-induced gene expression was identified using STAT-6 deficient knockout mice. Physiological studies demonstrate an inhibition of pulmonary eosinophil infiltration, mucus overproduction and AHR elicited by OVA challenge in mice harboring the STAT6 À/À null allele. 6, 15 Expression profiling of the lung tissue of STAT-6 deficient following multiple dose mIL-13 lung instillation did not reveal any genes that met the dual fold change and statistical criteria. Specifically, none of the IL-13 modulated genes in wild-type Balb/C mice were statistically different (Po0.05) from vehicle in the absence of STAT6 function. The differential response of Balb/C wild type and STAT6 À/À mice to multidose, intratracheal instillation of mIL13 is illustrated in Figure 3 . The IL-13 induced genes in wild-type mice were sorted by expression in OVA-challenge murine lung tissue and compared to frequency values obtained for similarly treated mice harboring the STAT6 À/À allele. Pulmonary gene expression from both buffer and IL-13 treated STAT6 À/À cohorts mirrors the expression of buffer-treated wild-type mice. These data demonstrate the requirement for STAT6 function for all of the measured mIL-13 mediated gene induction in the Balb/C wild type, consistent with the lack of physiological response to allergen challenge in the STAT6 À/À null mice.
Discussion
We previously demonstrated that administration of a soluble IL-13 antagonist to OVA challenged mice inhibited two critical aspects of the asthma phenotype, AHR and mucus production. 8, 9 Similarly, we have shown that intratracheal instillation of mIL-13 induced IgE, pulmonary eosinophilia, mucus production and AHR. 8, 9, 16 In this study, we have extended our analysis of this model using microarray expression profiling and have identified genes uniquely associated with IL-13 activity and antagonism. In addition, we have demonstrated a substantial overlap in gene expression changes following OVA challenge and intratracheal instillation of IL-13.
Mucus secretion and airway plugging have been shown to be consistent features of human asthma, asthma associated mortality 17 and of the OVA challenge murine model. In our study, we identified multiple IL-13 induced genes previously implicated in mucus expression and function, including AGR2/Gob-4, RegIII gamma, and IgGBP, trefoil factors (TFF1 and 2). Expression of these genes was completely dependent on IL-13 and STAT6 signaling. TFF2 and CLCA3/Gob-5, expressed by epithelial cells and associated with the presence of goblet cells and mucus production, were recently implicated in preclinical lung inflammation models and in genetic studies of human asthma. 18, 19 However, the induction of other mucus associated genes including AGR2/ Gob-4, RegIII gamma and FCGBP, following IL-13 administration and their dependence on IL-13 and STAT6 signaling have not been previously reported.
In mouse lung, CLCA3/Gob-5 mRNA expression is induced by STAT6-dependent IL-13 stimulation and allergen mediated induction of the CLCA3 transcript is completely dependent on IL-13 signaling. In addition to CLCA3, intratracheal instillation of IL-13 induced ion channel associated genes SLCA4a2, FXDY3, Guanylin and carbonic Table 3 .
anhydrase II. Expression of these genes was not observed in direct OVA-challenge profiles. The murine guanylin gene, encodes a 15 amino-acid endogenous ligand regulator of the intestinal guanylate cyclase-C regulator, STaR. 20 Activation of intestinal STaR induces a chloride secretion generating an accumulation of water in the gut and subsequent diarrhea. Typically, guanylin expression is restricted to intestinal epithelium; however, guanylin has been shown to activate outwardly rectifying chloride current in normal human bronchial epithelial cells. 21 The IL-13 mediated induction of guanylin and its activity in airway epithelial cells may be significant to the mucosal edema observed in asthmatic airways and its role in airway obstruction. These results are consistent with an emerging awareness of the involvement of chloride flux in the asthma pathology.
Consistent with the results of Zimmermann and coworkers, 18, 22 we showed that two members of the trefoil family, P-domain protein (TFF1/pS2) and spasmolytic protein (TFF2/mSP), were induced by OVA challenge. We now show that trefoil expression was completely dependent on IL-13 signaling. Trefoil proteins, small secretory proteins, are characteristic constituents of mucus gels and associated with cellular sites of mucin production. 23, 24 The upregulation of TFF-proteins by allergic-challenge or IL-13 thus may have dual roles of exacerbating the airway mucus obstruction while mediating a protective role in repair of the inflammatory damage to the epithelium.
OVA challenge and IL-13 exposure induced the expression of several members of the complement cascade, including C1q, C3 and properdin. We demonstrate that the IL-13 induction of C3 is dependent on STAT6 signaling. Furthermore, for the first time show that C3 gene expression is partially inhibited (50% of Ova-induced expression) by administration of sIL-13Ra2-Fc to OVA challenged mice. These findings are of particular interest in the light of the recent demonstration that C3 is critical for the development of allergen induced AHR in guinea pig and murine asthma models and pulmonary viral infection. [25] [26] [27] [28] Furthermore, recent studies have shown that the levels of the complement anaphylatoxin peptides are elevated in the lungs of asthmatic patients. 26 Although further studies are clearly needed to elucidate the exact sequence of events and site of C3 expression in our model, and the involvement of C3 in induction of Th2 cytokines and AHR, 29 our studies suggest that IL-13 induced AHR may be mediated via the local induction of complement C3 gene expression.
Our studies also identified a limited number of additional functional categories following IL-13 administration not detected with OVA challenge. For example, four genes were identified in the category of coagulation regulation, one of which, tissue plasminogen activator, was recently identified in a murine model of lung inflammation and studied in a murine model of asthma. The initiators of the extrinsic coagulation cascade, tissue factor and Factor VII were also induced by IL-13 consistent with results from a murine asthma model showing fibrin deposition in airways and BAL and demonstration of thrombin in the airways of asthmatic patients. 30 Together these results provide further evidence for abnormalities in procoagulant and fibrinolytic pathways in asthma and support further study in this area.
In combination, these findings support the reliability of this approach by demonstrating that many genes or gene families identified in this study, including small proline-rich proteins, chloride channels, complement proteins, have been shown to be associated with either asthma, epithelial cell metaplasia, or AHR. Furthermore, instillation of mIL-13 recapitulated all the gene expression increases observed with OVA-challenge except the elevation of Ig mRNA levels. The lack of increase in Ig mRNA concentration following pulmonary mIL-13 administration may reflect timing or more likely lack of antigen-specific signaling supporting Bcell expansion and trafficking. 31 Pulmonary administration of mIL-13 also resulted in identification of additional genes within the OVA challenge functional categories and additional functional categories. We view the expanded gene set measured in IL-13-treated lungs as a reflection of an increased strength of signal mediated by intratracheal cytokine instillation. We cannot, however, rule out temporal differences in expression or potential factors induced in the OVA-challenge allergic reaction that act to moderate or attenuate certain aspects of the IL-13 specific pathway.
The experiments described here demonstrate the power of gene expression profiles to provide a global view of diseaserelated transcription and response to therapy. Understanding gene expression profiles associated with asthma and the clinical features of AHR and increased mucus production may elucidate key players in the molecular pathway of the disease. IL-13 has been suggested to play a key role in the pathogenesis of bronchial asthma and is critical in inducing an allergic asthma response in animal models. 32, 33 Using an animal model of asthma, we have identified genes regulated by IL-13 whose functions are consistent with disease pathology induced by OVA challenge. In particular, the induction of genes associated with AHR and mucus production suggests a molecular pathway for the observed IL-13 effects that are consistent with a role in human asthma.
Therapeutic intervention with a soluble IL-13 antagonist confirms the direct role of IL-13 in the induction of these genes. These preclinical data also suggest that a comparison of gene expression changes in asthma and following therapeutic intervention be applied in clinical studies to monitor patient response to drug at a molecular level. This work has identified potential new targets for drug development as well as candidate markers of drug response in the treatment of asthma. Taken together these results further support the central role of IL-13 in asthmatic pathophysiology and the therapeutic value of antagonism of IL-13 in human asthma.
Methods

Experimental design
Balb/C wild-type mice (6-8 weeks of age) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). STAT6 deficient and wild-type controls were generated and bred on a Balb/C background as previously described. 34 All animals used in this study were housed in an environmentally controlled, pathogen-free facility under laminar flow hoods. All experiments conformed to the principals for laboratory animal research as outlined in the Animal Welfare Act and the Department of Health, Education and Welfare (NIH) guidelines for the experimental use of animals.
To identify transcriptional changes in genes associated with OVA challenge or therapy Balb/C mice (six per group) were immunized by an i.p. injection of 10 mg of OVA (Sigma, St Louis, MO, USA) in 200 ml of PBS on day 0. On days 14 and 25, mice were anesthetized with a mixture of ketamine and xylazine (45 and 8 mg/kg) and challenged intratracheally with 50 ml of a 1.5% solution of OVA or an equivalent volume of PBS. Two animals from each group were injected i.p. either with 100 ml of PBS, hIgG (400 mg/ml) or sIL-13Ra2-Fc (400 mg/ml) on days 24, 25 and 27. Purification of hIgG, sIL-13Ra2-Fc and murine IL-13 was as described previously. 35, 36 Lungs were collected and snap frozen for RNA isolation on day 28.
To identify transcriptional changes associated with pulmonary IL-13 expression, wild-type Balb/C mice were treated with intratracheal instillation of recombinant IL-13 (n ¼ 6) or PBS-buffer control. To elucidate the role of STAT6 signaling, the STAT6 À/À null allele was backcrossed into the Balb/C genetic background and treated with intratracheal instillation of either mIL-13 (n ¼ 5) or PBS buffer control (n ¼ 4) using an identical protocol and schedule as for the Balb/C wild-type mice. Recombinant murine IL-13 (5 mg in 50 ml) was administered daily for 3 days by intratracheal instillation to naïve Balb/c mice or STAT6 deficient mice that had been anesthetized with a mixture of ketamine and xylazine (45 and 8 mg/kg, respectively). Lungs were collected and snap frozen in dry ice at 72 h after the initial mIL-13 administration.
RNA isolation and hybridization to oligonucleotide arrays Snap frozen mouse lung tissue was pulverized using liquid nitrogen chilled mortar and pestle, suspended in 6 ml 4 M guanidinium isothiocyanate/0.7% 2-mercaptoethanol (GTC/ME) and pulse sonicated for 2 min. The tissue suspension was extracted twice with acid equilibrated phenol (Promega Total RNA Kit) and nucleic acid precipitated with an equal volume of isopropanol. The pellet was resuspended in 0.8 ml GTC/ME, re-extracted twice with an equal volume of acid phenol and once with chloroform. RNA was ethanol precipitated, suspended in DEPC treated H 2 O and quantified by OD 280 .
cDNA was synthesized from 10 mg of total RNA using the Superscript Kit (BRL) with modifications described in detail previously. 37 First strand synthesis was carried out at 501C to prevent mispriming from ribosomal RNA and utilized a T7 RNA polymerase promoter containing poly-T primer (T7T24) for subsequent in vitro antisense RNA (cRNA) amplification and biotin labeling. cDNA was purified using BioMag Carboxyterminated beads (Polysciences), according to the manufacturer's instructions, and eluted in 48 ml of 10 mM Na acetate pH 7.8.
In vitro T7 polymerase driven transcription reactions for synthesis and biotin labeling of antisense cRNA, Qiagen RNeasy spin column purification and cRNA fragmentation were performed as described. 12 GeneChip s hybridization mixtures contained 10 mg fragmented cRNA, 0.5 mg/ml acetylated BSA, 0.1 mg/ml herring sperm DNA, in 1 Â MES buffer in a total volume of 200 ml, as per the manufacturer's instructions. An 11 member standard curve was added to each hybridization mixture at concentrations ranging from 0.5 to 150 pM representing RNA frequencies of approximately 3.3 to 1000 parts per million (p.p.m.), assuming an average transcript size of 2 kb. The biotinylated standard curve fragments were synthesized by T7-polymerase driven IVT reactions from plasmid-based templates. 36 The biotinylated RNA fragments serve both as an internal standard to assess chip sensitivity and as standard curve to convert measured fluorescent difference averages from individual genes into RNA frequencies in p.p.m. 37, 38 Reaction mixtures were hybridized for 18 h at 451C to Affymetrix Mu11KsubA and Mu11KsubB oligonucleotide arrays that interrogate over 13 000 murine sequences. The hybridization mixtures were removed and the arrays were washed and stained with Streptavidin R-phycoerythrin (Molecular Probes) using the GeneChip s Fluidics Station 400 and scanned with a Hewlett-Packard GeneArray Scanner following the manufacturer's instructions. Fluorescent data were collected and converted to gene specific difference averages using MicroArray Suite 4.0 software. Technical parameters used to confirm gene chip sensitivity and overall quality are described in Supplemental Material (Table 1) .
Oligonucleotide array data analysis Average fluorescence difference between perfect match and single mismatch probe sets containing gene-specific oligonucleotides were used to determine frequency values with respect to spiked standard curve. In addition, a second set of algorithms based primarily on the fraction of individual positive or negative responding probe pairs, is used to assess the absolute presence or absence of the gene product. 12 The sensitivity of the individual microarray chip was set at onehalf the minimum concentration at which two of any three adjacent standard curve spike-in templates are called present. The standard curve linear regression is forced through zero and the minimum reported gene frequency was set to the sensitivity of the individual GeneChip s . Multiple independent replicas for each of the treatment or control experimental conditions were measured and the expression data was initially filtered to remove probe sets that were not called present in minimally four-files (minimum cohort size). Mean mRNA frequency values computed for the 5361 genes that passed the present-call filter were compared for treatment and control animals to obtain AFC and two-tailed Student's t-tests assuming unequal covariance of frequency.
FDR was calculated by randomization of the input data as described by Reiner et al.
14 Sample labels were randomly reassigned 10 000 times and the gene filtering and statistical analysis that had been executed on the observed data was repeated on each randomly permuted dataset. The median number of genes jointly meeting t-test P-value and absolute value of fold change criteria over the 10 000 random permutations was determined and the FDR is reported as this value divided by the number of genes meeting the criteria in the observed data. Because FDR was computed using the joint probability of t-test P-value and fold change, the reported FDR is not purely proportional to either P-value or fold change alone.
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